Abbott acquires co-marketing rights to arthritis drug

Article Abstract:

Miles D. White, Abbott Laboratories' new CEO admits his firm needs more new drugs in its pipeline, one reason for the co-marketing deal for selling German-made Mobic in the U.S. Another departure for the Illinois-based pharmaceuticals firm will be a more aggressive approach to mergers. Mobic is an arthritis pain reliever made by Boehringer Ingelheim GmbH. But it is not known whether the new drug will be effective without the gastrointestinal problems that most current arthritis drugs can cause. This is a chief reason for the success of Celebrex co-marketed by Monsanto and Pfizer .

Comment:

Signed co-marketing deal with Abbott Labs to sell Mobic in the US

Foreign operations, Germany, Strategic alliances, Geographic, Contracts, ABT, Abbott Laboratories (Abbott Park, Illinois), Boehringer Ingelheim GmbH

Heart devices market battle is revving up

Article Abstract:

The Intermedics pacemaker division of Swiss-based Sulzer Medica Ltd. will be acquired by Guidant Corp. in a deal that has been valued between $775 million and $850 million. Industry analysts have said that the deal will solidify Guidant's number two position in the $4 billion cardiac-rhythm devices market. Guidant, which is based in Indianapolis, In., plans to take advantage of Intermedics 200-person US sales force and 200-person overseas sales force in an increasingly competitive market for cardiac-rhythm devices.

Comment:

Will acquire Intermedics pacemaker division of Swiss-based Sulzer Medica Ltd. in a deal valued between $775 mil and $850 mil

Asset sales & divestitures, Acquisitions & mergers, Electromedical and Electrotherapeutic Apparatus Manufacturing, Medical Monitoring & Diagnostic Eqp, Pacemakers, Diagnostic equipment (Medical), Patient monitoring equipment, Guidant Corp., Article, Intermedics Inc.

Monsanto arthritis-pain drug, Celebrex, surpasses Viagra's early sales success

Article Abstract:

Monsanto's Celebrex for arthritis pain without causing severe stomach distress is showing signs of becoming the biggest selling prescription drug ever. The prediction is arrived at by comparing its number of prescriptions written to the number written for Viagra, currently the leader in early sales. Celebrex in only seven weeks has captured over 20% of the arthritis pain relief market.

Comment:

Celebrex can celebrate current market lead

Sales & consumption, Statistics, Monsanto Co., MTC, Antiarthritic agents